脓毒症急性期NT-proBNP水平对脓毒症幸存者长期躯体功能和肌力低下的预后价值
本研究为佛罗里达大学脓毒症与危重病研究中心(SCIRC)的回顾性分析,纳入196例18-86岁脓毒症患者,于脓毒症发病24小时检测NT-proBNP,随访至6个月和12个月,以简易躯体功能量表(SPPB,0-12分,分数越高躯体功能越好)和握力(公斤)评估躯体功能与上肢肌力。在校正年龄、性别、种族、查尔森合并症指数、APACHE II评分及是否合并慢性危重病(CCI)后,发病24小时NT-proBNP水平较高与12个月SPPB评分较低(p<0.05)、6个月握力较低(p<0.001)及12个月握力较低(p<0.05)相关。作者认为,脓毒症急性期NT-proBNP水平可能是有用的指标,提示脓毒症幸存者长期躯体功能和肌力损害风险较高。
要点
- 脓毒症发病24小时NT-proBNP较高与12个月SPPB评分较低独立相关(校正后p<0.05)。
- 脓毒症发病24小时NT-proBNP较高与6个月握力较低独立相关(校正后p<0.001)。
- 脓毒症发病24小时NT-proBNP较高与12个月握力较低独立相关(校正后p<0.05)。
- 校正变量包括年龄、性别、种族、查尔森合并症指数、APACHE II评分及是否合并CCI。
- 作者认为NT-proBNP可能是有用的指标,提示脓毒症幸存者长期躯体功能和肌力损害风险较高。
适用人群与场景
- 年龄18-86岁的脓毒症患者,来自佛罗里达大学(UF)脓毒症与危重病研究中心(SCIRC),同意参与12个月随访研究。
诊断标准与关键阈值
- 躯体功能采用简易躯体功能量表(SPPB)评分评估,量表范围0-12分,分数越高对应躯体功能越好。
- 上肢肌力采用握力测试评估,单位为公斤。
研究设计与关键结果
- 本研究为回顾性分析,纳入196例脓毒症患者,年龄18-86岁,为佛罗里达大学脓毒症与危重病研究中心(SCIRC)12个月随访研究的一部分。
- NT-proBNP于脓毒症发病24小时检测,随访至6个月和12个月评估SPPB评分和握力。
- 校正年龄、性别、种族、查尔森合并症指数、APACHE II评分及是否合并CCI后,发病24小时NT-proBNP较高与12个月SPPB评分较低相关(p<0.05)。
- 校正后,发病24小时NT-proBNP较高与6个月握力较低相关(p<0.001)。
- 校正后,发病24小时NT-proBNP较高与12个月握力较低相关(p<0.05)。
- 缺失随访数据或死亡导致的缺失采用基于同期健康状态评分的逆概率加权处理。
- 统计学显著性设定为p≤0.05。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症急性期NT-proBNP水平可能是有用的指标,提示脓毒症幸存者长期躯体功能和肌力损害风险较高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis survivors often develop chronic critical illness (CCI) and demonstrate the persistent inflammation, immunosuppression, and catabolism syndrome predisposing them to long-term functional limitations and higher mortality. There is a need to identify biomarkers that can predict long-term worsening of physical function to be able to act early and prevent mobility loss. N-terminal pro-brain natriuretic peptide (NT-proBNP) is a well-accepted biomarker of cardiac overload, but it has also been shown to be associated with long-term physical function decline. We explored whether NT-proBNP blood levels in the acute phase of sepsis are associated with physical function and muscle strength impairment at 6 and 12 months after sepsis onset.
METHODS: This is a retrospective analysis conducted in 196 sepsis patients (aged 18-86 years old) as part of the University of Florida (UF) Sepsis and Critical Illness Research Center (SCIRC) who consented to participate in the 12-month follow-up study. NT-proBNP was measured at 24 h after sepsis onset. Patients were followed to determine physical function by short physical performance battery (SPPB) test score (scale 0 to12-higher score corresponds with better physical function) and upper limb muscle strength by hand grip strength test (kilograms) at 6 and 12 months. We used a multivariate linear regression model to test an association between NT-proBNP levels, SPPB, and hand grip strength scores. Missing follow-up data or absence due to death was accounted for by using inverse probability weighting based on concurrent health performance status scores. Statistical significance was set at p ≤ 0.05.
RESULTS: After adjusting for covariates (age, gender, race, Charlson comorbidity index, APACHE II score, and presence of CCI condition), higher levels of NT-proBNP at 24 h after sepsis onset were associated with lower SPPB scores at 12 months (p < 0.05) and lower hand grip strength at 6-month (p < 0.001) and 12-month follow-up (p < 0.05).
CONCLUSIONS: NT-proBNP levels during the acute phase of sepsis may be a useful indicator of higher risk of long-term impairments in physical function and muscle strength in sepsis survivors.
参考来源
- Custodero C, Wu Q, Ghita GL, et al. Prognostic value of NT-proBNP levels in the acute phase of sepsis on lower long-term physical function and muscle strength in sepsis survivors. Crit Care. 2019. PMID: 31234943. doi:10.1186/s13054-019-2505-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。